Bank Julius Baer & Co. Ltd, Zurich Inhibrx, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Jul 23, 2021	SELL	$14.69 - $27.52 $2.06 Million - $3.87 Million	-140,566 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$16.27 - $41.26 $2.29 Million - $5.8 Million	140,566 New	140,566 $2.82 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.